Blog

The Utilization of AI for Prior Authorization: Pros, Cons, and Consumer Perspectives

By: Leah Turner In the ever-evolving world of healthcare, prior authorizations have long been a cumbersome process, burdening both insurers and healthcare providers. Recent developments in artificial intelligence (AI) are disrupting this process, offering the promise of efficiency and cost reduction. In this blog post, we'll delve into general feelings...
Read More

Keeping up with Generation Jones

By Brandon Dunk On a day-to-day basis, demographic shifts are nearly unnoticeable. But in the long run, it’s also important to remember that demographics slowly shift the landscape much like a river. Hence the phrase, “Demography is destiny,” and its use as postmortem of those who failed while refusing to...
Read More

Explore Duals Plan Options with Our Simulator Tool

When you purchase either of our industry-leading Duals studies, you can now add on Deft’s powerful Dual Acquisition Simulator Tool for only $5,000 more. Our Dual Acquisition Simulator Tool is ideal for last-minute design checks. Use it to model supplemental benefit packages and purses based on nine areas examined in...
Read More

CMS’s HCC: A Medicare Battleground for Years to Come

By Brandon Dunk   CMS’s deadline for publishing its final rate announcement was April 3, 2023; in the end, it was able to release the information a little early on March 31st. Many of the worst fears of carriers were alleviated with the press release, where CMS expected the average...
Read More

Medicare Reimbursement Turmoil

by Brandon Dunk   Medicare Advantage carriers are counting down to April 3rd, and Deft Research is watching with them. April 3, 2023, is the date that CMS will publish its final rate announcement. These rates have already been previewed in the 2024 Medicare Advantage Prescription Drug (MAPD) Advance Notice,...
Read More

Navigating Medicare Disruption

In August of this year, the U.S. Congress passed the Inflation Reduction Act, which promises to lower costs and improve outcomes for American seniors. Beginning in 2026, the Secretary of the Department of Health and Human Services (HHS) will choose a selection from the most expensive Part D drugs each year to come under negotiated price restrictions. Other changes are pending...
Read More
< Previous Next >

Let's Chat

To learn more, please submit your contact info below and we’ll get right back to you.

By clicking the submit button, I expressly consent by electronic signature to receive communications via automatic telephone dialing system or by artificial/prerecorded message, email or by text message from this website and multiple partner companies or their agents at the telephone number above (even if my number is currently listed on any state, federal, local or corporate Do Not Call list) including my wireless number if provided, for the purpose of marketing insurance products and services. Carrier message and data rates may apply. I understand that my consent is not required as a condition of purchasing any goods or services and that I may revoke my consent at any time. I also acknowledge that I have read and agree to the Privacy Policy and Terms & Conditions.